A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)

A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)

Vaccination of the population is one of the most effective countermeasures in responding to the pandemic caused by novel coronavirus infection. Therefore, scientists all over the world have been working to develop effective and safe vaccines. We have developed a synthetic peptide vaccine, EpiVacCoro...

Full description

Saved in:
Bibliographic Details
Main Authors: A. B. Ryzhikov, Е. А. Ryzhikov, M. P. Bogryantseva, S. V. Usova, E. D. Danilenko, E. A. Nechaeva, O. V. Pyankov, O. G. Pyankova, A. S. Gudymo, S. A. Bodnev, G. S. Onkhonova, E. S. Sleptsova, V. I. Kuzubov, N. N. Ryndyuk, Z. I. Ginko, V. N. Petrov, A. A. Moiseeva, P. Yu. Torzhkova, S. A. Pyankov, T. V. Tregubchak, D. V. Antonec, E. V. Gavrilova, R. A. Maksyutov
Format: article
Language:RU
Published: Sankt-Peterburg : NIIÈM imeni Pastera 2021
Subjects:
epivaccorona
peptide vaccine
clinical trials
covid-19
coronavirus
Infectious and parasitic diseases
RC109-216
Online Access:https://doaj.org/article/7df779e259364aabaefcf269dea25ef1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/7df779e259364aabaefcf269dea25ef1

Similar Items